Obiettivo The TRACVAC Consortium will eliminate the global problem of blinding trachoma through the development of a vaccine. Our strategy of the project will eliminate two important bottlenecks for the development of a trachoma vaccine 1) The lack of neutralizing antibody responses to vaccine preparations based on MOMP 2) The challenge of inducing vaccine promoted sustained local ocular IgA.TRACVAC has two main objectives. The first main objective is to generate a vaccine that protect against the bacterial strains causing ocular Chlamydia trachomatis infections. To accomplish this we first select naturally protected individuals from high endemic regions and identify all neutralizing epitopes from the major outer membrane antigen (MOMP) of Chlamydia trachomatis through the unique combination of the B cell cloning and high density array technology. The epitopes will be produced as vaccines through the use of the immuno-repeat technology that is known to increase the quality and quantity of the vaccine promoted response. The second main objective is to develop an immunization protocol for optimal ocular mucosal immunity. To do this we will establish an ocular non-human primate (NHP) challenge model and use this to test different prime boost vaccination strategies for ocular responses and protection against challenge. We will subsequently test the best strategy in a clinical phase I evaluation of a trachoma vaccine based on a immuno-repeat construct targeting serovar B. This will provide early human proof of concept both for the immuno-repeat technology and the prime boost strategy for ocular IgA. In summary, TRACVAC will deliver a final vaccine candidate targeting the main ocular serovars and a vaccine protocol ready to enter a clinical phase I trial.TRACVAC is highly relevant for the topic (Vaccine development for malaria and/or neglected infectious diseases), as the aim is to accelerate vaccine development against the neglected infectious disease Trachoma. Campo scientifico medical and health scienceshealth sciencesinfectious diseasesmalariamedical and health scienceshealth sciencespublic healthmedical and health sciencesbasic medicineimmunologyimmunisationmedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccinesmedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibiotics Parole chiave Clinical trial Infectious disease Bacteria Immunology Chlamydia Trachoma Programma(i) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.2. - Preventing disease Argomento(i) SC1-PM-06-2016 - Vaccine development for malaria and/or neglected infectious diseases Invito a presentare proposte H2020-SC1-2016-2017 Vedi altri progetti per questo bando Bando secondario H2020-SC1-2016-RTD Meccanismo di finanziamento RIA - Research and Innovation action Coordinatore STATENS SERUM INSTITUT Contribution nette de l'UE € 2 099 187,50 Indirizzo ARTILLERIVEJ 5 2300 Kobenhavn S Danimarca Mostra sulla mappa Regione Danmark Hovedstaden Byen København Tipo di attività Research Organisations Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Partecipazione a programmi di R&I dell'UE Opens in new window Rete di collaborazione HORIZON Opens in new window Costo totale € 2 099 187,50 Partecipanti (3) Classifica in ordine alfabetico Classifica per Contributo netto dell'UE Espandi tutto Riduci tutto LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE ROYAL CHARTER Regno Unito Contribution nette de l'UE € 1 012 655,75 Indirizzo KEPPEL STREET WC1E 7HT London Mostra sulla mappa Regione London Inner London — West Camden and City of London Tipo di attività Higher or Secondary Education Establishments Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Partecipazione a programmi di R&I dell'UE Opens in new window Rete di collaborazione HORIZON Opens in new window Costo totale € 1 012 655,75 COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES Francia Contribution nette de l'UE € 1 945 433,75 Indirizzo RUE LEBLANC 25 75015 PARIS 15 Mostra sulla mappa Regione Ile-de-France Ile-de-France Paris Tipo di attività Research Organisations Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Partecipazione a programmi di R&I dell'UE Opens in new window Rete di collaborazione HORIZON Opens in new window Costo totale € 1 945 433,75 IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE Regno Unito Contribution nette de l'UE € 1 617 220,50 Indirizzo SOUTH KENSINGTON CAMPUS EXHIBITION ROAD SW7 2AZ LONDON Mostra sulla mappa Regione London Inner London — West Westminster Tipo di attività Higher or Secondary Education Establishments Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Partecipazione a programmi di R&I dell'UE Opens in new window Rete di collaborazione HORIZON Opens in new window Costo totale € 1 617 220,50